转移性激素敏感性前列腺癌最佳系统治疗:STOPCAP系统综述与网状Meta分析
该研究基于10项已完成试验和1项进行中试验的汇总数据,纳入6项试验共6204例男性,进行网状Meta分析。结果显示,与单用ADT相比,AAP联合ADT的OS获益最大(HR=0.61,95%CI 0.53-0.71),Doc联合ADT次之(HR=0.77,95%CI 0.68-0.87)。结论支持AAP或Doc联合ADT用于转移性激素敏感性前列腺癌,AAP可能是最有效治疗。
要点
- AAP联合ADT的OS HR为0.61(95%CI 0.53-0.71),为最优方案。
- Doc联合ADT的OS HR为0.77(95%CI 0.68-0.87),为次优方案。
- ZA联合Cel的OS HR为0.78(95%CI 0.62-0.97),效应与单药相加一致。
核心结论
- 结果支持AAP或Doc联合ADT用于转移性激素敏感性前列腺癌男性。
- AAP似乎是最有效治疗,但其优势是否源于真实获益或试验差异尚不明确。
研究设计与样本
- 基于汇总数据的网状Meta分析,纳入10项已完成试验和1项进行中试验,主要分析基于6项试验共6204例男性。
- 主要终点为总生存期(OS),同时分析无失败生存期。
主要发现
- 与单用ADT相比,AAP联合ADT的OS HR=0.61(95%CI 0.53-0.71)。
- 与单用ADT相比,Doc联合ADT的OS HR=0.77(95%CI 0.68-0.87)。
- 与单用ADT相比,ZA联合Cel的OS HR=0.78(95%CI 0.62-0.97)。
- 与单用ADT相比,ZA联合Doc的OS HR=0.79(95%CI 0.66-0.94)。
- 与单用ADT相比,Cel单药的OS HR=0.94(95%CI 0.75-1.17),ZA单药的OS HR=0.90(95%CI 0.79-1.03)。
关键数值与推荐
- AAP成为最有效治疗的概率:OS为94%,无失败生存期为100%。
- Doc成为OS第二优治疗的概率为35%。
临床怎么用
- 对于转移性激素敏感性前列腺癌男性,可考虑AAP或Doc联合ADT。
- AAP可能优先作为最有效方案,但需结合患者个体特征和试验差异综合决策。
局限性
- 基于汇总数据而非个体参与者数据,无法充分调整患者变异、预后变化和治疗效应随时间变化。
- AAP的优势是否真实优于其他治疗尚不明确,可能受试验特征影响。
- 正在进行基于个体参与者数据的网状Meta分析以克服上述局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc), but not zoledronic acid (ZA), were added to androgen-deprivation therapy (ADT). Trial evidence also suggests a benefit of combining celecoxib (Cel) with ZA and ADT. To establish the optimal treatments, a network meta-analysis (NMA) was carried out based on aggregate data (AD) from all available studies. METHODS: Overall survival (OS) and failure-free survival data from completed Systemic Treatment Options for Cancer of the Prostate reviews of Doc, ZA and AAP and from recent trials of ZA and Cel contributed to this comprehensive AD-NMA. The primary outcome was OS. Correlations between treatment comparisons within one multi-arm, multi-stage trial were estimated from control-arm event counts. Network consistency and a common heterogeneity variance were assumed. RESULTS: We identified 10 completed trials which had closed to recruitment, and one trial in which recruitment was ongoing, as eligible for inclusion. Results are based on six trials including 6204 men (97% of men randomised in all completed trials). Network estimates of effects on OS were consistent with reported comparisons with ADT alone for AAP [hazard ration (HR) = 0.61, 95% confidence interval (CI) 0.53-0.71], Doc (HR = 0.77, 95% CI 0.68-0.87), ZA + Cel (HR = 0.78, 95% CI 0.62-0.97), ZA + Doc (HR = 0.79, 95% CI 0.66-0.94), Cel (HR = 0.94 95% CI 0.75-1.17) and ZA (HR = 0.90 95% CI 0.79-1.03). The effect of ZA + Cel is consistent with the additive effects of the individual treatments. Results suggest that AAP has the highest probability of being the most effective treatment both for OS (94% probability) and failure-free survival (100% probability). Doc was the second-best treatment of OS (35% probability). CONCLUSIONS: Uniquely, we have included all available results and appropriately accounted for inclusion of multi-arm, multi-stage trials in this AD-NMA. Our results support the use of AAP or Doc with ADT in men with metastatic hormone-naive prostate cancer. AAP appears to be the most effective treatment, but it is not clear to what extent and whether this is due to a true increased benefit with AAP or the variable features of the individual trials. To fully account for patient variability across trials, changes in prognosis or treatment effects over time and the potential impact of treatment on progression, a network meta-analysis based on individual participant data is in development.
引用
- Vale CL, Fisher DJ, White IR, et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol. 2018. PMID: 29788164. doi:10.1093/annonc/mdy071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。